Tamara Aripova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tamara Aripova has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Shukhrat Khudaiberdievich Ziyadullaev
Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Tashkent
4 shared publications - Adolat A. Ismailova
Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Tashkent
2 shared publications - Javdat N. Muratkhodjaev
Institute of Immunology and Human Genomics Academy of Sciences of Uzbekistan
2 shared publications - Kh.M. Khatamov
Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Tashkent
2 shared publications - Зайнитдин Камалов
Институт иммунологии и геномики человека АН РУз
2 shared publications - A'Zamjon Raximjonov
Institute of Immunology and Human Genomics, Tashkent, Uzbekistan
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Preprints.org
Clinical, Immunological, Biochemical and Safety Outcomes of Eryxin (Reptilin) in Human Studies: A Systematic Review of Published and Grey Literature
Background. Eryxin (Reptilin), an aqueous snake autolysate developed in Uzbekistan, has been used since the 1990s as an immunomodulating agent. Its clinical evidence is dispersed across published and grey literature.Objective. To identify and appraise human studies of Eryxin or Reptilin and summarise their clinical, immunological, biochemical and safety outcomes.Methods. We searched PubMed, Europe PMC, Google Scholar, eLIBRARY.ru, CyberLeninka, three trial registries, libraries and archives; the last search update was on 30 September 2026. Human studies of any design with extractable data were eligible. Authors independently extracted data with artificial-intelligence assistance; discrepancies were checked against original scans. Two reviewer pairs independently assessed risk of bias for prioritised outcomes using the 2016 Risk Of Bias In Non-randomised Studies of Interventions tool for controlled studies and the National Heart, Lung, and Blood Institute before–after tool for uncontrolled studies. Synthesis was descriptive without meta-analysis. Certainty was summarised by condition and for adverse events using the Grading of Recommendations Assessment, Development and Evaluation approach.Results. Twenty-two non-randomised studies across 16 conditions were included (64 reports), all conducted in Uzbekistan. A reliable total number of unique participants was unavailable because of uncertain cohort overlap and inconsistent participant counts. Most reports were retrieved from libraries and archives. Eleven of 16 controlled studies were at serious and five at critical risk of bias; all six uncontrolled studies were rated poor. Eryxin was added to other treatment in all but one arm. Favourable clinical and laboratory findings were reported, but interpretation was limited by confounding, incomplete reporting and, in some studies, differing co-interventions. Immunological findings varied across conditions and regimens without establishing a consistent response. Reporting gaps or inconsistencies were identified in 18 studies. Reported adverse events included transient taste or odour, flushing, tachycardia, fever and rash; ascertainment and denominators were inconsistent. Recorded certainty ratings were very low across conditions and for adverse events.Conclusions. The evidence does not establish effectiveness for any studied condition. This does not demonstrate absence of an effect. Overall and comparative safety remain uncertain. Well-conducted randomised controlled trials are needed to determine clinical benefits and harms.
- 6 November 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical, Immunological, Biochemical and Safety Outcomes of Eryxin (Reptilin) in Human Studies: A Systematic Review of Published and Grey Literature
Background. Eryxin (Reptilin), an aqueous snake autolysate developed in Uzbekistan, has been used since the 1990s as an immunomodulating agent. Its clinical evidence is dispersed across published and grey literature.Objective. To identify and appraise human studies of Eryxin or Reptilin and summarise their clinical, immunological, biochemical and safety outcomes.Methods. We searched PubMed, Europe PMC, Google Scholar, eLIBRARY.ru, CyberLeninka, three trial registries, libraries and archives; the last search update was on 30 September 2026. Human studies of any design with extractable data were eligible. Authors independently extracted data with artificial-intelligence assistance; discrepancies were checked against original scans. Two reviewer pairs independently assessed risk of bias for prioritised outcomes using the 2016 Risk Of Bias In Non-randomised Studies of Interventions tool for controlled studies and the National Heart, Lung, and Blood Institute before–after tool for uncontrolled studies. Synthesis was descriptive without meta-analysis. Certainty was summarised by condition and for adverse events using the Grading of Recommendations Assessment, Development and Evaluation approach.Results. Twenty-two non-randomised studies across 16 conditions were included (64 reports), all conducted in Uzbekistan. A reliable total number of unique participants was unavailable because of uncertain cohort overlap and inconsistent participant counts. Most reports were retrieved from libraries and archives. Eleven of 16 controlled studies were at serious and five at critical risk of bias; all six uncontrolled studies were rated poor. Eryxin was added to other treatment in all but one arm. Favourable clinical and laboratory findings were reported, but interpretation was limited by confounding, incomplete reporting and, in some studies, differing co-interventions. Immunological findings varied across conditions and regimens without establishing a consistent response. Reporting gaps or inconsistencies were identified in 18 studies. Reported adverse events included transient taste or odour, flushing, tachycardia, fever and rash; ascertainment and denominators were inconsistent. Recorded certainty ratings were very low across conditions and for adverse events.Conclusions. The evidence does not establish effectiveness for any studied condition. This does not demonstrate absence of an effect. Overall and comparative safety remain uncertain. Well-conducted randomised controlled trials are needed to determine clinical benefits and harms.
- 1 January 2026
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 47 (4)
Immunomodulatory effect of intravenous immunoglobulin in patients with inflammatory dilated cardiomyopathy
- 1 January 2026
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 47 (4)
Immunomodulatory effect of intravenous immunoglobulin in patients with inflammatory dilated cardiomyopathy
- Open Access
- 31 August 2025
- Published by Salidat Kairbekova National Research Center for Health Development in Journal of Health Development
- Vol. 60 (4)
Организация помощи пациентам с редкими заболеваниями: Международный опыт и векторы развития для Содружества Независимых Государств
Rare diseases are a significant healthcare challenge, affecting over 300 million people worldwide across more than 7,000 conditions, most of which manifest in childhood and have a severe chronic course. In May 2025, the World Health Assembly adopted WHO Resolution WHA78.11, formally recognizing rare diseases as a global health priority. This review aims to analyze the key provisions of the resolution and their implementation in countries with different healthcare models: France, Japan, Brazil, and Saudi Arabia.Data were collected from official governmental and international sources, scientific publications, and analytical reports from 2018 to 2025. The analysis shows that sustainable development of rare disease care systems requires the development and implementation of national strategies and plans, the establishment of centers of expertise, the advancement of digitalinfrastructure, the integration of real-world data, and the application of innovative financing mechanisms, including managed entry agreements and outcome-based payment models. The findings may inform national approaches tailored to the local context.
- 31 August 2025
- Published by Salidat Kairbekova National Research Center for Health Development in Journal of Health Development
- Vol. 60 (4)
Open AccessОрганизация помощи пациентам с редкими заболеваниями: Международный опыт и векторы развития для Содружества Независимых Государств
Rare diseases are a significant healthcare challenge, affecting over 300 million people worldwide across more than 7,000 conditions, most of which manifest in childhood and have a severe chronic course. In May 2025, the World Health Assembly adopted WHO Resolution WHA78.11, formally recognizing rare diseases as a global health priority. This review aims to analyze the key provisions of the resolution and their implementation in countries with different healthcare models: France, Japan, Brazil, and Saudi Arabia.Data were collected from official governmental and international sources, scientific publications, and analytical reports from 2018 to 2025. The analysis shows that sustainable development of rare disease care systems requires the development and implementation of national strategies and plans, the establishment of centers of expertise, the advancement of digitalinfrastructure, the integration of real-world data, and the application of innovative financing mechanisms, including managed entry agreements and outcome-based payment models. The findings may inform national approaches tailored to the local context.
- Open Access
Experimental Confirmation of Osteoarthritis Repair In Vivo Using Epigenetic Reprogramming with Small Chemical Molecules
Osteoarthritis (OA) is a progressive degenerative joint disease that significantly impairs mobility and quality of life, particularly in aging populations. Current therapeutic approaches primarily focus on symptom relief, but fail to address the underlying mechanisms of cartilage degeneration. In recent years, epigenetic reprogramming has emerged as a promising strategy for cellular rejuvenation, offering new perspectives for regenerative medicine. This study investigates the potential of a selected set of small chemical molecules (SCM) to induce epigenetic reprogramming of chondrocytes and promote cartilage regeneration in an in vivo model of chemically induced OA. The experiments were conducted on aging female rats, a translational model chosen for its relevance to human age-related OA and postmenopausal cartilage deterioration. OA was induced via intra-articular administration of trypsin, and a subset of animals was further subjected to estrogen receptor blockade using clomiphene citrate to simulate postmenopausal conditions. The SCM cocktail was administered intra-articularly to evaluate its effects on cartilage repair. Chondroitin sulfate was used as a comparative treatment control. The results demonstrated that SCM administration led to significant improvements in joint tissue integrity, including increased cartilage thickness, enhanced synthesis of mucopolysaccharides, and restoration of chondrocyte metabolic activity. Histological analysis revealed that SCM-treated groups exhibited reduced cartilage erosion, lower inflammatory marker expression, and improved nuclear-cytoplasmic index (NCI) values, suggesting enhanced chondrocyte function. Notably, the group with estrogen receptor blockade responded more favorably to SCM treatment than the non-blocked OA group, highlighting the potential interaction between hormonal status and epigenetic reprogramming. These findings provide strong evidence for the feasibility of epigenetic modulation as a therapeutic strategy for OA. The ability of SCMs to restore cartilage structure and function suggests a novel approach to treating age-related degenerative diseases. Further research is required to elucidate the precise molecular mechanisms underlying this rejuvenation process and optimize therapeutic protocols for clinical applications.
Open AccessExperimental Confirmation of Osteoarthritis Repair In Vivo Using Epigenetic Reprogramming with Small Chemical Molecules
Osteoarthritis (OA) is a progressive degenerative joint disease that significantly impairs mobility and quality of life, particularly in aging populations. Current therapeutic approaches primarily focus on symptom relief, but fail to address the underlying mechanisms of cartilage degeneration. In recent years, epigenetic reprogramming has emerged as a promising strategy for cellular rejuvenation, offering new perspectives for regenerative medicine. This study investigates the potential of a selected set of small chemical molecules (SCM) to induce epigenetic reprogramming of chondrocytes and promote cartilage regeneration in an in vivo model of chemically induced OA. The experiments were conducted on aging female rats, a translational model chosen for its relevance to human age-related OA and postmenopausal cartilage deterioration. OA was induced via intra-articular administration of trypsin, and a subset of animals was further subjected to estrogen receptor blockade using clomiphene citrate to simulate postmenopausal conditions. The SCM cocktail was administered intra-articularly to evaluate its effects on cartilage repair. Chondroitin sulfate was used as a comparative treatment control. The results demonstrated that SCM administration led to significant improvements in joint tissue integrity, including increased cartilage thickness, enhanced synthesis of mucopolysaccharides, and restoration of chondrocyte metabolic activity. Histological analysis revealed that SCM-treated groups exhibited reduced cartilage erosion, lower inflammatory marker expression, and improved nuclear-cytoplasmic index (NCI) values, suggesting enhanced chondrocyte function. Notably, the group with estrogen receptor blockade responded more favorably to SCM treatment than the non-blocked OA group, highlighting the potential interaction between hormonal status and epigenetic reprogramming. These findings provide strong evidence for the feasibility of epigenetic modulation as a therapeutic strategy for OA. The ability of SCMs to restore cartilage structure and function suggests a novel approach to treating age-related degenerative diseases. Further research is required to elucidate the precise molecular mechanisms underlying this rejuvenation process and optimize therapeutic protocols for clinical applications.
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (2)
The experience of using omalizumab biosimilar in patients with atopic bronchial asthma and clinically significant sensitization to aeroallergens in the Republic of Uzbekistan
Опыт применения биоаналога омализумаба у пациентов с атопической бронхиальной астмой и клинически значимой сенсибилизацией к аэроаллергенам в
- 1 January 2025
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 46 (2)
Open AccessThe experience of using omalizumab biosimilar in patients with atopic bronchial asthma and clinically significant sensitization to aeroallergens in the Republic of Uzbekistan
Опыт применения биоаналога омализумаба у пациентов с атопической бронхиальной астмой и клинически значимой сенсибилизацией к аэроаллергенам в
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Immune changes in synovial fluid in rheumatoid arthritis
Иммунные изменения в синовиальной жидкости при ревматоидном артрите
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (5)
Open AccessImmune changes in synovial fluid in rheumatoid arthritis
Иммунные изменения в синовиальной жидкости при ревматоидном артрите
- Open Access
- 31 October 2022
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 24 (5) , 1065-1074
RNA interference is the basis of human antiviral defense
Comparative analysis of antiviral protective mechanisms in protozoa and RNA interference of multicellular organisms has revealed their similarity, also providing a clue to understanding the adaptive immunity. In this article, we present the latest evidence on the importance of RNA-guided gene regulation in human antiviral defense. The role of neutralizing antibodies and interferon system in viral invasion is considered. The new concept has been introduced, i.e., antiviral protection of any living organism is based on the intracellular RNA-guided mechanisms. Simple and effective defense against viruses is that spacer segment of the viral DNA is inserted into the cellular chromosomes. Upon re-infection, the RNA transcript of the spacer directs nuclease enzymes against the foreign genome. This is a really adaptive immune defense that any cell potentially possesses. In humans, the interferon system provides an additional tool for early suppression of viral infections which shifts the cells to the alert regimen, thus preventing further spread of infection. The main task of the human central immune system is to maintain integrity and combat foreign organisms. Accordingly, a suitable index of acquired antiviral immunity should be a presence of specific spacer markers in DNA samples from reconvalescent persons, rather than detection of neutralizing antibodies, B and T memory cells.This article is addressed primarily to general medical community, and its practical conclusions are as follows:1. Presence or absence of specific antibodies to SARS-CoV-2 is not a prognostic sign of the disease. Detection of specific antibodies in blood simply reflects the fact that the person has contacted with the viral agent. Absence of antibodies does not mean a lack of such contact, and the persons with high titers of specific antibodies are not protected from re-infection with SARS-CoV-2.2. PCR testing: The PCR results may remain “false positive” in those subjects who have had COVID-19, if the genetic material is taken from the site of initial virus contraction (mainly, nasopharynx). In our opinion, negative PCR tests for COVID-19 in blood plasma and urine will be a more correct index for the absence of the disease, even with positive PCR tests from the nasopharyngeal samples.3. It is necessary to draw attention of general practitioners to potential usage of retinol in prevention and treatment of COVID-19, given the importance of RLR receptors in recognition of viral RNAs and positive experience of vitamin A administration in measles, another dangerous viral disease.
- 31 October 2022
- Published by SPb RAACI in Medical Immunology (Russia)
- Vol. 24 (5) , 1065-1074
Open AccessRNA interference is the basis of human antiviral defense
Comparative analysis of antiviral protective mechanisms in protozoa and RNA interference of multicellular organisms has revealed their similarity, also providing a clue to understanding the adaptive immunity. In this article, we present the latest evidence on the importance of RNA-guided gene regulation in human antiviral defense. The role of neutralizing antibodies and interferon system in viral invasion is considered. The new concept has been introduced, i.e., antiviral protection of any living organism is based on the intracellular RNA-guided mechanisms. Simple and effective defense against viruses is that spacer segment of the viral DNA is inserted into the cellular chromosomes. Upon re-infection, the RNA transcript of the spacer directs nuclease enzymes against the foreign genome. This is a really adaptive immune defense that any cell potentially possesses. In humans, the interferon system provides an additional tool for early suppression of viral infections which shifts the cells to the alert regimen, thus preventing further spread of infection. The main task of the human central immune system is to maintain integrity and combat foreign organisms. Accordingly, a suitable index of acquired antiviral immunity should be a presence of specific spacer markers in DNA samples from reconvalescent persons, rather than detection of neutralizing antibodies, B and T memory cells.This article is addressed primarily to general medical community, and its practical conclusions are as follows:1. Presence or absence of specific antibodies to SARS-CoV-2 is not a prognostic sign of the disease. Detection of specific antibodies in blood simply reflects the fact that the person has contacted with the viral agent. Absence of antibodies does not mean a lack of such contact, and the persons with high titers of specific antibodies are not protected from re-infection with SARS-CoV-2.2. PCR testing: The PCR results may remain “false positive” in those subjects who have had COVID-19, if the genetic material is taken from the site of initial virus contraction (mainly, nasopharynx). In our opinion, negative PCR tests for COVID-19 in blood plasma and urine will be a more correct index for the absence of the disease, even with positive PCR tests from the nasopharyngeal samples.3. It is necessary to draw attention of general practitioners to potential usage of retinol in prevention and treatment of COVID-19, given the importance of RLR receptors in recognition of viral RNAs and positive experience of vitamin A administration in measles, another dangerous viral disease.
- 1 January 1978
- No. 1,p. 35-7
[Development and forms of epidemiological health service organization in Samarkand Province].
- 1 January 1978
- No. 1,p. 35-7
[Development and forms of epidemiological health service organization in Samarkand Province].